

1 **KASP-PCR method to screen thrombophilia genetic risk**
2 **factors**

3

4 **Reham Altwayan^{1,2}, Huseyin Tombuloglu^{2*}, Abdulrahman Alhusil³, Taghreed**
5 **Awadh³, Mona Altwayan³, Heba Albaqawi³, Noof Aldossary³, Turgay Unver⁴**

6

7 ¹Master Program of Biotechnology, Institute for Research and Medical Consultations, Imam
8 Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

9 ²Department of Genetics Research, Institute for Research and Medical Consultations (IRMC),
10 Imam Abdulrahman Bin Faisal University, 31441, Dammam, Saudi Arabia

11 ³Department of Internal Medicine, King Fahad Military Medical Complex, Dhahran, Saudi
12 Arabia

13 ⁴Department of Computer Engineering, Ostim Technology University, Ankara, Turkey

14

15 [*htoglu@iau.edu.sa](mailto:htoglu@iau.edu.sa)

16

17 **Abstract**

18 Thrombophilia is defined as the willingness of blood to clot easily in a situation of
19 imbalances between fibrinolysis and coagulation. It is classified as inherited and
20 acquired thrombophilia. Several studies revealed that the inherited thrombophilia is
21 strongly associated with single nucleotide polymorphisms (SNP) or deletions on certain
22 genes, such as *FV Leiden (rs6025)*, *MTHFR1 (rs1801133)*, *MTHFR2 (rs1801131)*,
23 *Serpine-1 (rs1799768)*, and *Factor II (rs1799963)*. This study aims to develop an SNP
24 detection panel based on Kompetitive Allele Specific Primer-polymerase chain reaction
25 (KASP-PCR) technique. Results revealed that 86.5% of susceptible patients (n = 111)
26 contain at least one mutation; while seven of them harbor three thrombophilia-associated
27 mutations simultaneously. A clear allelic discrimination was observed for all tested
28 samples. The prevalence of each mutation among different countries and ethnic groups
29 are in line with the findings of this study. Rather than expensive and time-consuming
30 approaches, the current assay enables the cost-effective advantage of the KASP-PCR,
31 which reduces the diagnostic cost with a fast and convenient way. After clinical
32 validation and approval, it can be used in hospitals, research centers, and diagnostic
33 laboratories to determine the genetic susceptibility of individuals to thrombosis and for
34 research purposes.

35

36 **Keywords:** SNP, thrombophilia, prevalence, molecular diagnosis, mutation.

37

38 **Introduction**

39 Thrombophilia is defined by the World Health Organization/International Society of
40 Thrombosis and Hemostasis (WHO/ISTH) as an abnormal tendency to coagulation or
41 clotting of the blood in a part of the circulatory system (WHO, 1995). The disease poses
42 a significant health burden. According to the CDC reports, >900,000 people in the
43 United States alone are affected by blood clots each year, with substantial mortality
44 rates. Due to thrombophilia-related complications, 60,000 to 100,000 deaths are
45 recorded in the USA annually, which is greater than the total number of people who lose
46 their lives each year from AIDS, breast cancer, and motor vehicle crashes combined
47 (Badireddy & Mudipalli, 2022). The disease is classified as inherited and acquired

48 thrombophilia. Inherited thrombophilia is associated with four SNPs and one deletion
49 mutations located in different genes, namely: coagulation *factor II (FII)*, coagulation
50 *factor V (FV)*, *5,10- methylene tetrahydrofolate reductase (MTHFR1 and MTHFR2)*,
51 and *serpine1 (SERPINE1)* (Yapjajakis et al, 2015).

52 Diagnostic approaches include detecting disorders by examining clinical signs,
53 imaging techniques, and analysis through molecular aspects. Direct DNA genotyping,
54 PCR-based techniques, immunological detection, and chromogenic assays are used to
55 identify thrombophilia-related disorders (Linnemann and Hart 2019). Sequencing
56 techniques are the most accurate approaches followed and used for validation purposes.
57 On the other hand, PCR-based approaches such as TaqMan, KASP and rhAmp are
58 mostly used due to their simplicity, timesaving, cost-effectiveness, and ability to
59 measure the heterozygosity or homozygosity of mutations carried among thrombophilia
60 genes.

61 Kompetitive Specific Allele Primer-PCR (KASP-PCR) is a fluorescent-based
62 reporting system to identify and measure the SNPs (He et al., 2014). It is used to
63 differentiate between species in plants and animals (Yang et al., 2020). KASP-PCR
64 technique is fast, sensitive, relevant, and cost-effective (Alvarez-Fernandez et al., 2021;
65 Zhang et al., 2020). Due to the cost advantage, it has been applied widely in plant
66 breeding for commercial use (Makhoul et al., 2020). KASP technique is precise, and its
67 specificity is based on the competitive nature of allele specific forward primers and
68 modified Taq polymerase.

69 The current genotyping techniques are based on sequencing or PCR, which are
70 time consuming and expensive methods. Therefore, a cost-effective, time-saving, and
71 accurate technique is needed to screen symptomatic and asymptomatic suspicious
72 people. This study aims to screen thrombophilia associated SNPs based on KASP-PCR
73 technique. For this purpose, the DNA samples of thrombophilia-susceptible patients (n =
74 111) were collected and five associated mutations on *FV Leiden*, *MTHFR1*, *MTHFR2*,
75 *Serpine-1*, and *Factor II* genes were identified. Rather than expensive and time-
76 consuming approaches, the current assay reduces the diagnostic cost in a fast and
77 convenient way.

78

79 **Material and Methods**

80 **Collection of blood samples and ethical concerns**

81 5 mL of leftover whole blood samples were retrieved from King Fahad Military Medical
82 Complex (KFMHC) (IRB Protocol No: AFHER-IRB-2022-031). A total of 111 samples
83 have been collected from thrombophilia-susceptible patients who have been admitted to
84 the hospital with thrombophilia symptoms, such as chest pain, abdominal pain,
85 dizziness, fever, seizure, breath shortness, etc. The blood samples were collected in an
86 Ethylenediamine tetra acetic acid tube (EDTA) and stored at -20 °C until DNA
87 extraction.

88

89 **Extraction of DNA**

90 QIAamp® DNA Blood Mini Kit 250 (QIAGEN) was used to extract and purify DNA.
91 The instructions of the manufacturer were followed. The final eluate was kept at -20 °C
92 for further stages. NanoDrop™ 2000/2000c spectrophotometer was used to quantify the
93 purity and concentration of extracted DNA samples. The samples were also visualized in
94 agarose gel for 20 min at 100 Volt and monitored under UV light (Molecular Imager®
95 ChemiDoc™ XRS+, Bio-Rad). Image Lab™ Software (Bio-Rad) was utilized to save
96 the images.

97

98 **Primer design**

99 Primers corresponding to the SNP positions were manually designed. First, the
100 corresponding gene sequences were retrieved from NCBI database
101 (<https://www.ncbi.nlm.nih.gov>) and Primer Blast tool was used to pick the primers. In
102 addition, Primer 3 program was used to verify the designed primers: one common
103 reverse, two alternating forward primers that are specific to the SNP positions.

104

105 **Validation of plate reader and KASP-PCR reaction**

106 Before genotyping, KASP genotyping validation kit (LOW ROX KASP TF Validation
107 kit, LGC) was used to validate the plate-reader instrument (7500 Fast Real-Time PCR
108 System). According to the manufacturer's protocol, the compatibility and readability of
109 the plate reader was confirmed. The kit consists of three tubes of diluted fluorophores:
110 FAM, HEX, and HEX/FAM. The tubes were briefly vortexed and dispensed into a
111 microtiter plate. Then, KASP reagents (2x KASP master mix, and 72x KASP assay mix)
112 with provided DNA samples (n = 36) were used to run the following protocol: (1) 94 °C

113 15 minutes for activation (1 cycle); (2) 94 °C 20 sec for denaturation and 61-55 °C 60
114 sec (drop 0.6 °C per cycle) for annealing/elongation (10 cycles); (3) 94 °C 20 sec for
115 denaturation and 55 °C 60 sec for annealing/elongation (26 cycles). At the end of the
116 reaction, the endpoint fluorescent reading was performed. To obtain the best genotyping
117 clusters, the plate underwent two rounds of recycle steps, as follows: 94 °C 20 sec for
118 denaturation, and 57 °C for 60 sec for annealing/elongation (3 cycles).

119

120 **Genotyping of thrombophilia-associated SNPs with KASP-PCR**


121 The KASP primer mixture for each target SNPs was prepared including 12 µl of
122 forward-1 primer, 12 µl of forward-2 primer, 30 µl of common reverse primer, and 46 µl
123 of distilled water to reach the total volume of 100 µl. Then, 5 µl of master mixture
124 (KASP™ TF Low ROX Master Mix) and 0.14 µl of assay mixture were added and
125 vortexed briefly. In 96 well plate, 5 µl of assay mixture was added with 5 µl of DNA
126 sample in each well and then sealed tightly. The KASP genotyping assay was performed
127 by using real-time PCR 7500 (Applied Biosystem) instrument.

128

129 **RESULTS**

130 **Calibration and optimization of KASP protocol**

131 Before the KASP-PCR reaction for the discrimination of thrombophilia-associated
132 SNPs, the validity of the fluorescent thermal cycler and the protocol for KASP-PCR
133 were optimized and validated. Nine positive control samples (LGC Bioscience), labeled
134 with FAM (blue), HEX (red), and FAM/HEX (green) fluorophores, were used to
135 optimize, and verify the fluorescence signals that will be obtained from the thermal
136 cycler. **Figure 1** depicts the cluster plot of FAM, HEX, and FAM/HEX labeled positive
137 control samples. The clusters correspond to homozygote dominant (allele 1/allele 1),
138 homozygote recessive (allele 2/allele 2), and heterozygote (allele 1/allele 2)
139 discriminations. This result showed optimized and successful KASP-PCR reaction
140 conditions with calibrated fluorometric measurements.




141

142 **Figure 1.** The allelic discrimination plot of FAM (blue), HEX (red) and FAM/HEX
143 (green) fluorophores. Three samples used for each positive control dyes.

144

145 Furthermore, the optimized protocol was used to discriminate real DNA samples
146 (n = 45) provided by the LOW ROX KASP TF Validation kit (LGC Biosciences). In
147 addition to the DNA samples, three negative control samples were included. After the
148 KASP-PCR reaction, the allelic discrimination plot was depicted in **Figure 2**. The results
149 were shown before (**Figure2A**) and after three (**Figure2B**) and six (**Figure2C**) additional
150 recycling stages. After six recycling stages, positive and negative samples were clearly
151 separated, and the negative control specimens were placed near the origin side of the plot.
152 In addition, the homozygote and heterozygote alleles were determined to be well-
153 clustered. It is obvious that additional recycling steps improved the allelic discrimination,
154 where the best and most efficient results were obtained upon six additional recycling
155 stages (**Figure 2C**).

156



157


158 **Figure 2.** Validation of plate reader and KASP-PCR protocol. Allelic discrimination
159 plot of DNA samples (n = 45). A) Without recycle step. B) After the addition of three
160 recycling steps. C) After the addition of six recycling steps. Black dots indicate the
161 negative control sample. Red, blue, and green dots indicate the homozygotes of Allele 1,
162 homozygotes of Allele 2, and heterozygotes of Allele 1/2.

163

164

165 **KASP-PCR genotyping of rs6025 (G1691A) on the Factor V Leiden gene**

166 An optimized KASP-PCR protocol was performed to identify the G1691A substitution
167 on the *FVL* mutation (*FV* gene, rs6025). **Figure 3.** shows the discrimination plots of
168 samples. Since the total sample number (n = 111) is more than the capacity of the
169 thermal cycler (n = 96), the reaction was completed in two separate runs. Upon the
170 KASP-PCR reaction, an additional six recycling steps was added for the best reaction
171 performance. Black dots indicate negative control, green dots indicate heterozygote
172 sample (CT), and blue dots indicate homozygote (CC). Accordingly, only one sample
173 was detected as heterozygote (~1%), and the rest of the samples were homozygote wild
174 (~99%). This result shows that almost all thrombophilia-susceptible individuals admitted
175 to the hospital are free of *FVL* gene mutation.
176




177
178 **Figure 3.** The figure shows the discrimination plot of FVL mutation with an additional 6
179 cycles. Black dots indicate negative control, green dot indicate heterozygote sample
180 (CT), and blue dots indicate homozygote wild (CC).

181

182 **KASP-PCR genotyping of (rs1799963) (G20210A) on the *FII* gene**

183 KASP-PCR assay was performed to screen the G20210A variation on the *FII-PT* gene.
184 **Figure 4.1** depicts the discrimination plots of extracted DNA samples. Since the

185 capacity of the PCR plate is 96 wells, the run was divided into two runs. In addition to
186 the KASP-PCR thermal cycle, six more recycling step was added to improve
187 discrimination. Black dots refer to negative control, placed near the plot's origin side;
188 blue dots refer to homozygote wild samples (GG); red dot sample is homozygote mutant
189 (AA), while no green dots of heterozygote recorded. Only one sample was recorded as
190 homozygote recessive, while the rest of the sample was homozygote dominant, and no
191 heterozygote detected. This result shows that only one of the susceptible thrombophilia
192 patients carried the *FII-PT* mutation.
193




194
195 **Figure 4.1** Shows the discrimination plot of *Factor II* mutation with an additional 6
196 cycles. Black dots indicate negative control, blue dots indicate homozygote wild (GG),
197 and red dots indicate homozygote mutant (AA).

198 199 **KASP-PCR genotyping of (rs1801133) on the *MTHFR* gene**

200 After optimization of the KASP-PCR assay, screening for mutation on *MTHFR1* was
201 performed (*MTHFR* gene, rs1801133). **Figure 25** illustrates the discrimination plot of
202 susceptible-thrombophilia patient samples. The reaction was completed in two runs due
203 to the number of samples (n=111). In addition, six recycling steps were added to obtain
204 clear discrimination. Four black dots refer to negative control and are correctly placed

205 near the origin of the plot, green dots refer to the heterozygote sample (CT), and red dots
206 refer to the homozygote sample (CC). Consequently, 24 % of the patients were
207 heterozygote, only two samples were recorded as homozygote recessive (TT) (~2%),
208 and the rest of the samples were recorded as homozygote dominant. This result shows
209 that ~26% of the patients admitted to the hospital with a risk of developing
210 thrombophilia are carrying at least one allele of *MTHFR1* mutation.
211




212
213 **Figure 2.** Shows the Allelic Discrimination Plot of *MTHFR* rs1801133 (C/T) mutation
214 with an additional 6 cycles. Black dots indicate negative control; green dots indicate
215 heterozygote (CT); and red dots indicate homozygote mutant (TT); blue dots indicate
216 homozygote.

217 218 **KASP-PCR genotyping of (rs1801131) on the *MTHFR2* gene**

219 An optimized KASP-PCR assay was achieved to screen the mutation placed on the
220 *MTHFR2* gene (rs1801131). **Figure 3** demonstrates the discrimination plot of two runs
221 performed on extracted DNA samples. With the addition of six thermal recycling steps,
222 the reaction shows the best performance. Black dots imply negative control; green dots
223 imply heterozygote sample (AC), blue dots imply homozygote wild (AA), and red dots
224 imply homozygote recessive (CC) alleles. Discrimination results showed that ~53% of

225 the patients admitted to the hospital are free of mutation (wild), 39% carrying this
226 mutation in one allele, and 6.3% carrying two alleles of mutation. The result shows that
227 ~45% of susceptible thrombophilia patients have at least one mutation.
228




229
230 **Figure 3.** Shows the Allelic Discrimination Plot of *MTHFR* rs1801131 mutation with
231 the addition of 3 cycles. Black dots indicate negative control; red dots indicate
232 homozygote mutant (CC), green dots indicate heterozygote (AC), and blue dots indicate
233 homozygote wild.

234

235 **KASP-PCR genotyping of *Serpine 1* (rs1799768)**

236 Genetic screening for *Serpine 1* (rs1799768) mutation was performed by optimized
237 KASP-PCR assay. **Figure 7** shows the discrimination plot of the (n=111) sample
238 divided into two runs due to the capacity of the thermal cycler. Black dots indicate
239 negative control, and it is successfully placed near the origin of the plot; blue dots
240 indicate homozygote dominant 5G/5G, green dots indicate heterozygote 5G/4G and red
241 dots indicate homozygote recessive 4G/4G. Unlike other genes, only three additional
242 thermals are needed to obtain clear discrimination of samples. Therefore, 47 of the
243 sample was detected as homozygote dominant (~42%), 44 of the sample were detected
244 as heterozygote by carrying one mutation (~39%), and 17 were detected as homozygote

245 recessive (~15%). The result shows that more than 50% of patients harbor *Serpine 1*
246 mutation, which increases the risk of developing thrombophilia.
247



248
249 **Figure 7.** Shows the discrimination plot of *Serpine 1* rs1799768 mutation with an
250 additional 3 cycles. Black dots indicate negative control, red dots indicate homozygote
251 mutant (4G/4G), green dots indicate heterozygote (5G/4G), and blue dots indicate
252 homozygote wild.

253

254 DISCUSSION

255 This study aims to screen genetic risk factors in patients susceptible to thrombophilia
256 disease by applying the cost-effective PCR technique (KASP-PCR). For this purpose,
257 left-over blood samples (n = 111) collected from thrombophilia symptomatic patients
258 were utilized for genetic screening. Approximately 30% of the cases were admitted to
259 the hospital with chest pain and 20% with abdominal pain. In addition to these
260 symptoms, vomiting (2.7%), shortness of breath (11%), palpitations (4.5%), dizziness
261 (10%), and fever (5.5%) were among the most common symptoms recorded. Patients
262 who apply to the hospital with suspicion of the disease are aged 5-92 (mean = 52), male
263 and female (62 male, 50 female).

264 KASP-PCR analyses revealed that 92 out of 111 (~83%) patients susceptible to
265 thrombophilia carry at least one of the analyzed mutations. The age and gender were not
266 found to be associated with thrombophilia-related polymorphisms ($P > 0.05$). Before
267 KASP-PCR genotyping testing, the KASP genotyping validation kit was used to
268 optimize and validate the plate reader. The device was calibrated according to the
269 passive reference dye ROX™ contained in the KASP master mixture. Optimal FAM,
270 HEX, and FAM/HEX fluorescence signals were checked and adjusted for the most
271 efficient signal score. **Figure 1.** shows successful discrimination in testing FAM, HEX,
272 and FAM/HEX dyes; where FAM is clustered in the Y-axis direction, HEX is clustered
273 in the X-axis opposite direction, while the FAM/HEX mixture is clustered in the middle.
274 Moreover, the cycle and re-cycling stages were optimized to obtain the best allelic
275 discrimination (**Figure2**). Results revealed that two rounds of three re-cycling steps (six
276 in total) provided the most efficient protocol for robust allelic discrimination.

277 The primary role of the *FV* gene is regulating the production of coagulation
278 factor V protein. A mutation found in this gene (G1691A) substitutes arginine to
279 glutamine amino acid at point 506 in a polypeptide of Factor V (Arg506Gln) (Madkhaly
280 et al., 2021), leading to unresponsiveness to anticoagulant factors (C and S) (Kujovich,
281 2018). The risk of developing thrombophilia is five times higher in heterozygotes and 50
282 times higher in homozygotes, and it is responsible for 20-25% of all VTE cases (Bezgin
283 et al., 2018). It was found to be the most critical genetic risk factor related to
284 thrombophilia (Djordjevic et al., 2012). The prevalence of *FVL* among the European
285 population is high, while it is rare in Eastern Asia and Africa. Since the Arab countries
286 are geographically at the center. The prevalence of *FVL* mutation in different countries
287 and ethnic groups are listed in **Table 1.** Our results showed that all collected samples are
288 homozygote wild, except one sample which is heterozygote (No. 61). In **Figure 3.**, the
289 heterozygote individual was admitted to the hospital with flank pain and dysuria. A
290 prospective study aims to evaluate the prevalence of *FVL* in 149 healthy Saudi subjects
291 revealed that 2% of the individuals are heterozygotes, and none of those individuals are
292 homozygotes mutant (0%) (Almawi et al., 2005). Golestani et al., (2022) investigated
293 the correlation between acute myocardial infarction (AMI) and *FVL* in the Iranian
294 population; 5.5% of cases were found to be heterozygotes, while 1% were homozygote
295 mutants. On the other hand, Gowda et al., (2000) found that among American subjects,

296 8% were heterozygote. Based on these results, the data in the literature is in line with
 297 and compatible with our results.

298 **Table 1** The prevalence of thrombophilia-associated SNPs according to different
 299 countries, ethnic groups, and this study.

Factor V Leiden	Genotype	Saudi Arabia	Caucasia	Asia	Lebanon	Tunisia	Bahrain	Saudi Arabia
	G/A	5.5%	7.5%	0%	13.8%	5.8%	3%	0.9%
	A/A	0.39%	0.2%	0%	1%	0.6%	0%	0%
	GG	94.11%	92.3%	100%	85.2%	93.6%	97%	99.1%
Reference		Madkhaly et al, 2021	Raptopoulou et al, 2022	Madkhaly et al, 2021	Almawi et al., 2005	Almawi et al., 2005)	Almawi et al., 2005	This study

300

Factor II	Genotype	Saudi Arabia	Caucasia	Asia	Jordan	Bahrain	Chechan	Saudi Arabia
	G/A	2.8%	4.1%	0.8%	5.7%	1%	1%	0%
	A/A	0.09%	0.2%	0%	2%	0%	0%	1%
	G/G	97.11%	95.7%	99.2%	92.3%	99%	99%	99%
Reference		Madkhaly et al, 2021	Madkhaly et al, 2021	Gunathilake et al, 2015	Al-Zoubi et al., 2021	Almawi et al., 2005	Dajani et al., 2012	This study

301

	Genotype	Saudi Arabia	Caucasia	Asia	Jordan	African America n	Lebanon	Saudi Arabia
MTHFR I	C/T	24%	49.3%	45%	%38	%26	30%	24%
	T/T	2.5%	35.9%	22%	10%	2.7%	4%	2%
	C/C	73.5%	14.8%	33%	52%	71.3%	66%	74%
MTHFR II	A/C	39%	40%	44%	50%	27%	50%	40%
	C/C	10%	11.5%	5%	12%	3.6%	24%	6%
	A/A	51%	48.5%	51%	38%	69.4%	26%	54%
Reference		AlGasham et al, 2011	Raptopoulou et al, 2021	Wang et al 2016	Yousef et al, 2013	Graydon et al, 2019	Sabbagh et al, 2008	This study

302

<i>Serpine-1</i>	Genotype	Saudi Arabia	Caucasia	Asia	Jordan	UK	Turkey	Saudi Arabia
	4G/5G	33.6%	51%	55%	39%	43%	40%	41%
	4G/4G	7.7%	23%	26%	27%	26%	26%	16%
	5G/5G	58.7%	26%	29%	34%	31%	34%	43%
Reference		Settin et al, 2012	Nikolopoulos et al, 2014	Xu et al, 2016	Al-Zoubi et al., 2021	Balta et al. 2003	Balta et al. 2003	This study

303

304 *Prothrombin* is a protein synthesized in the liver and is essential in clotting the
305 blood (Khan & Dickerman, 2006). As a result of the replacement of guanine with
306 adenine at position 20210 of the *coagulation factor II (FII)* gene (G20210A), high
307 concentrations of prothrombin protein are activated (Poudel et al., 2020; Ahmed et al.,
308 2020; Rennert & DeSimone, 2019). An increase in prothrombin level increases thrombin
309 level and inhibits Activated Protein C (APC) - inhibits FV protein-, subsequently
310 stimulating thrombus formation. Thus, the risk of VTE appearance increases. It is
311 estimated to be the second most important genetic risk factor causing thrombophilia
312 (Djordjevic et al., 2012). In our experiment, one out of 90 patients carry a homozygous
313 mutant allele (Patient No. 52, 86 years old male, and suffering from dysuria); no
314 mutation was detected in other samples (**Figure 4.14**). A study has been conducted to
315 screen *FII* and *FVL* mutations from eight years-old patient who is suffering from dysuria
316 and priapism. The genotyping result revealed that the patient was heterozygote for both
317 mutations (Özbek et al., 2003). At the same time, the patient is homozygote with *FII* and
318 heterozygote with *FVL*. A retrospective study showed that 2.6% of patients screened for
319 *FII* are positive through Saudi thrombosis patients (Madkhaly et al., 2021). A cross
320 sectional study investigate the prevalence of *FII* mutation in Jordanian population; 5.7%
321 were heterozygote while 2% were homozygote mutant (Al-Zoubi et al., 2021). A group
322 of healthy Arab population enrolled in a retrospective study to test the distribution of
323 *FII*. No mutated allele among Saudis was observed, while 1% of heterozygotes in
324 Bahraini. In Lebanese and Tunisian, 3.6% and 2.6% are heterozygotes, respectively
325 (Almawi et al., 2005). An amplification refractory mutation detection system (ARMS)
326 was applied to define the prevalence of *FII* in Chechans populations in Jordan; only 2%
327 of heterozygotes were detected, while no homozygote mutant (Dajani et al., 2012). The

328 fact that the mutation prevalence in the general population is 2-3% in the western region,
329 while rare in other geographical regions and all previous literature shows a rare
330 incidence of FII mutation, which reflects KASP-PCR results.

331 The *MTHFR* gene decreases homocysteine concentration by producing the
332 MTHFR enzyme to convert the homocysteine to methionine (Hickey et al., 2013; Dean,
333 2016). Two recognized mutations in the *MTHFR* gene inactivate the enzyme, leading to
334 increased levels of homocysteine and decreased levels of folate in plasma: C677T
335 (rs1801133) and A1286C (rs1801131) (Dölek et al., 2007). The American Congress of
336 Obstetricians and Gynecologists recommends screening for *MTHFR* mutations instead
337 of homocysteine concentration in patients at risk of thrombophilia (Hickey et al., 2013).
338 In our experiment, we detected these mutations using KASP-PCR method. The
339 prevalence of C677T (rs1801133) was ~2% with homozygote mutant, ~24%
340 heterozygote, and ~75% homozygote wild (**Figure 25**). Whereas the prevalence of
341 A1286C (rs1801131) was ~6% homozygote, ~40% heterozygote, and ~55%
342 homozygote wild (**Figure 36**). The prevalence of C677T among Hispanics is over 25%
343 and between 10-15% among Caucasians and North Americans with homozygote type
344 (Hickey et al., 2013). Dajani et al, (2013). Investigating the prevalence of C677T among
345 Chechen and Circassians healthy individuals; 27.5% of Chechen carry the mutation,
346 while 50% of Circassians. A study reported that 31% of patients with stroke carried
347 heterozygosity of C677T, while 15% were homozygote mutants. The higher incidence of
348 that variant is attributed to other risk factors, such as smoking and hypertension
349 (Djordjevic et al., 2012).

350 A variation in the *serpine 1* gene is represented by the deletion of 4G/5G alleles
351 in position 675 in chromosome 7 at the promoter region (Xu et al., 2016; Isordia-Salas et
352 al., 2009; Tsai et al., 2008). The role of the *serpine1* gene is to synthesize plasminogen
353 activator inhibitor 1 (PAI-1), and the mutation increases production (Morange et al.,
354 2007). High concentration of PAI-1 leads to inhibit plasmin from fibrinolysis, causing to
355 accumulate clots in veins (Heit MD, 2013; Morange et al., 2007; Kazuo Miyashita et al.,
356 2012). The allelic discrimination of KASP-PCR of this mutation showed that ~40% of
357 samples are heterozygote, while 14.4% were detected as homozygote mutant (**Figure 7**.
358 **7**). In total, 54% of patients carried PAI-1 variation. Yapikajis et al., (2012) conducted a
359 genotyping study using blood samples from a healthy Greek population, and 49% were
360 found mutated. A case-control study was performed to define the correlation between

361 high concentration of PAI-1 and developing ischemic stroke in young Indian patients.
362 Akhter et al., (2017) found that 62% of young Indian patients have PAI-1 SNP. Xu et
363 al., (2016) found that ~46% of chronic obstructive pulmonary disease through Chinese
364 Han patients were heterozygote, while ~14% were homozygote mutants. These results
365 are in line with the current findings (Table 1).

366

367 **Conclusion**

368 A gene panel covering five thrombophilia associated mutations (*Serpine 1*, *MTHFR1*,
369 *MTHFR2*, *Factor V Leiden*, and *Factor II*) was developed based on the KASP-PCR
370 assay to diagnose thrombophilia genetic risk factors. The variety of diagnostic tests, the
371 unreliability of clinical judgment, and a delayed diagnosis could lead to illnesses that
372 may increase mortality and morbidity. In addition, molecular-based analyses are highly
373 costly and time-consuming to obtain accurate results compared to the KASP-PCR assay.
374 The KASP-PCR assay is a cost-effective (~2-3 dollar per reaction), timesaving (3-4
375 hours), non-invasive, accurate, and highly sensitive. In this study, we obtained a clear
376 allelic discrimination for all samples tested to screen SNPs related to thrombophilia.
377 Rather than expensive and time-consuming approaches, the current assay enables the
378 cost-effective advantage of the KASP-PCR assay, which reduces the diagnostic cost
379 with a fast and convenient way. After clinical validation and approval, it can be used in
380 hospitals, research centers, and diagnostic laboratories to determine the genetic
381 susceptibility of individuals to thrombosis and also for research purposes.

382

383 **Acknowledgment** This study is funded by the Deanship of Graduate Studies under
384 project number 2023-003-IRMC. The figures are created with BioRender.com.

385

386 **Compliance with Ethical Standards**

387 **Conflict of interest** The authors declare that they have no conflict of interest.

388

389 **Authors' contributions**

390 HT and RA conceptualized the study. RA and HT conducted the experiments. RA, and
391 HT wrote the manuscript. AA, TA, MA, HA, NA, AIA identified the patients and
392 provided the samples. TU revised and commented on the manuscript.

393

394

395

396 **References**

397

398 •Wang X, Fu J, Li Q, Zeng D. Geographical and Ethnic Distributions of the MTHFR
399 C677T, A1298C and MTRR A66G Gene Polymorphisms in Chinese Populations:
400 A Meta-Analysis. *PLoS One*. 2016 Apr 18;11(4):e0152414. doi:
401 10.1371/journal.pone.0152414. PMID: 27089387; PMCID: PMC4835080.

402 Akhter MS, Biswas A, Abdullah SM, Behari M, Saxena R. The Role of PAI-1 4G/5G
403 Promoter Polymorphism and Its Levels in the Development of Ischemic Stroke in
404 Young Indian Population. *Clin Appl Thromb Hemost*. 2017 Nov;23(8):1071-1076.
405 doi: 10.1177/1076029617705728. Epub 2017 May 1. PMID: 28460568.

406 Algasham, A., Ismail, H., Dowaidar, M., & Settin, A. A. (2011).
407 Methylene tetrahydrofolate Reductase (MTHFR) and Angiotensin Converting
408 Enzyme (ACE) Gene Polymorphisms among Saudi Population from Qassim
409 Region. *International Journal of Health Sciences*, 5(2 Suppl 1), 3.

410 Almawi WY, Keleshian SH, Borgi L, Fawaz NA, Abboud N, Mtiraoui N, Mahjoub T.
411 Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single
412 nucleotide polymorphisms among Arabs. *J Thromb Thrombolysis*. 2005
413 Dec;20(3):163-8. doi: 10.1007/s11239-005-3550-4. PMID: 16261289.

414 Alvarez-Fernandez, A., Bernal, M. J., Fradejas, I., Martin Ramírez, A., Md Yusuf, N.
415 A., Lanza, M., ... & Rubio, J. M. (2021). KASP: a genotyping method to rapid
416 identification of resistance in *Plasmodium falciparum*. *Malaria Journal*, 20(1), 1-8.

417 Al-Zoubi, N., Alrabadi, N., Kheirallah, K., & Alqudah, A. (2021). Prevalence and
418 Multiplicity of Thrombophilia Genetic Polymorphisms of FV, MTHFR, F II, and
419 PAI-I: A Cross-Sectional Study on a Healthy Jordanian Population. *International
420 Journal of General Medicine*, 5323-5332.

421 Badireddy M, Mudipalli VR. Deep Venous Thrombosis Prophylaxis. 2022 Aug 22. In:
422 StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.
423 PMID: 30521286.

424 Balta, G. Ü. N. A. Y., Altay, C., & Gurgey, A. Y. T. E. M. İ. Z. (2003). Prevalence of
425 PAI-1 gene 4G/5G genotype in Azerbaijan and Kyrgyzstan populations: literature
426 review. *Journal of Thrombosis and Haemostasis*, 1(4), 858-859.

427 Bezgin T, Kaymaz C, Akbal Ö, Yılmaz F, Tokgöz HC, Özdemir N. Thrombophilic
428 Gene Mutations in Relation to Different Manifestations of Venous

- 429 Thromboembolism: A Single Tertiary Center Study. *Clin Appl Thromb Hemost.*
430 2018 Jan;24(1):100-106. doi: 10.1177/1076029616672585. Epub 2016 Oct 11.
431 PMID: 27729560; PMCID: PMC6714624.
- 432 Dajani, R., Fatahallah, R., Dajani, A., Al-Shboul, M., & Khader, Y. (2012). Prevalence
433 of coagulation factor II G20210A and factor V G1691A Leiden polymorphisms in
434 Chechans, a genetically isolated population in Jordan. *Molecular biology reports,*
435 39, 9133-9138.
- 436 Dajani, R., Fathallah, R., Arafat, A., AbdulQader, M. E., Hakooz, N., Al-Motassem, Y.,
437 & El-Khateeb, M. (2013). Prevalence of MTHFR C677T single nucleotide
438 polymorphism in genetically isolated populations in Jordan. *Biochemical genetics,*
439 51, 780-788.
- 440 Dean L. Methylenetetrahydrofolate Reductase Deficiency. 2012 Mar 8 [updated 2016
441 Oct 27]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman
442 BL, Malheiro AJ, editors. *Medical Genetics Summaries* [Internet]. Bethesda
443 (MD): National Center for Biotechnology Information (US); 2012–. PMID:
444 28520345.
- 445 Djordjevic V, Stankovic M, Brankovic-Sreckovic V, Rakicevic L, Damnjanovic T,
446 Antonijevic N, Radojkovic D. Prothrombotic genetic risk factors in stroke: a
447 possible different role in pediatric and adult patients. *Clin Appl Thromb Hemost.*
448 2012 Nov;18(6):658-61. doi: 10.1177/1076029611432136. Epub 2012 Jan 23.
449 PMID: 22275392.
- 450 Dölek, B., Eraslan, S., Eroğlu, S., Kesim, B. E., Ulutin, T., Yalçiner, A., ... &
451 Gözükmızı, N. (2007). Molecular analysis of factor V Leiden, factor V Hong
452 Kong, factor II G20210A, methylenetetrahydrofolate reductase C677T, and
453 A1298C mutations related to Turkish thrombosis patients. *Clinical and Applied*
454 *Thrombosis/Hemostasis,* 13(4), 435-438.
- 455 Golestani, A., Rahimi, A., Moridi, N. et al. Association of factor V Leiden R506Q,
456 FXIIIVal34Leu, and MTHFR C677T polymorphisms with acute myocardial
457 infarction. *Egypt J Med Hum Genet* 23, 118 (2022).
458 <https://doi.org/10.1186/s43042-022-00330-9>.
- 459 Gowda, M.S., Zucker, M.L., Vacek, J.L. et al. Incidence of Factor V Leiden in Patients
460 with Acute Myocardial Infarction. *J Thromb Thrombolysis* 9, 43–45 (2000).
461 <https://doi.org/10.1023/A:1018652429633>

- 462 Graydon, J. S., Claudio, K., Baker, S., Kocherla, M., Ferreira, M., Roche-Lima, A., ... &
463 Ruaño, G. (2019). Ethnogeographic prevalence and implications of the 677C> T
464 and 1298A> C MTHFR polymorphisms in US primary care populations.
465 *Biomarkers in Medicine*, 13(8), 649-661.
- 466 He, Chunlin, John Holme, and Jeffrey Anthony. "SNP genotyping: the KASP assay."
467 *Crop breeding*. Humana Press, New York, NY, 2014. 75-86.
- 468 Hickey, S. E., Curry, C. J., & Toriello, H. V. (2013). ACMG Practice Guideline: lack of
469 evidence for MTHFR polymorphism testing. *Genetics in Medicine*, 15(2), 153-
470 156.
- 471 Isordia-Salas, I., Leaños-Miranda, A., Sainz, I. M., Reyes-Maldonado, E., & Borrayo-
472 Sánchez, G. (2009). Association of the plasminogen activator inhibitor-1 gene
473 4G/5G polymorphism with ST elevation acute myocardial infarction in young
474 patients. *Revista Española de Cardiología (English Edition)*, 62(4), 365-372.
- 475 John A. Heit, 14 - *Thrombophilia: Clinical and Laboratory Assessment and*
476 *Management*, Editor(s): Craig S. Kitchens, Craig M. Kessler, Barbara A. Konkle,
477 *Consultative Hemostasis and Thrombosis (Third Edition)*, W.B. Saunders, 2013,
478 Pages 205-239, ISBN 9781455722969, [https://doi.org/10.1016/B978-1-4557-](https://doi.org/10.1016/B978-1-4557-2296-9.00014-2)
479 [2296-9.00014-2](https://doi.org/10.1016/B978-1-4557-2296-9.00014-2).
480 (<https://www.sciencedirect.com/science/article/pii/B9781455722969000142>)
- 481 Joint, W. H. O. (1995). *Inherited thrombophilia: report of a Joint WHO* (No.
482 WHO/HGN/ISTH/WG/95.5. Unpublished). World Health Organization.
- 483 Kazuo Miyashita, Show Nishikawa, Masashi Hosokawa, Chapter 29 - Therapeutic
484 Effect of Fucoxanthin on Metabolic Syndrome and Type 2 Diabetes, Editor(s):
485 Debasis Bagchi, Nair Sreejayan, *Nutritional and Therapeutic Interventions for*
486 *Diabetes and Metabolic Syndrome*, Academic Press, 2012, Pages 367-379, ISBN
487 9780123850836, <https://doi.org/10.1016/B978-0-12-385083-6.00029-2>.
- 488 Kujovich, J. L. (2018). Factor V Leiden thrombophilia.
- 489 Linnemann, B., & Hart, C. (2019). Laboratory diagnostics in thrombophilia.
490 *Hämostaseologie*, 39(01), 049-061.
- 491 Madkhaly F, Alshaikh A, Alkhail HA, Alnounou R, Owaidah T. Prevalence of positive
492 factor V Leiden and prothrombin mutations in samples tested for thrombophilia in
493 Saudi Arabia. *Am J Blood Res*. 2021 Jun 15;11(3):255-260. PMID: 34322288;
494 PMCID: PMC8303010.

- 495 Makhoul M, Rambla C, Voss-Fels KP, Hickey LT, Snowdon RJ, Obermeier C.
496 Overcoming polyploidy pitfalls: a user guide for effective SNP conversion into
497 KASP markers in wheat. *Theor Appl Genet.* 2020 Aug;133(8):2413-2430. doi:
498 10.1007/s00122-020-03608-x. Epub 2020 Jun 4. PMID: 32500260; PMCID:
499 PMC7360542.
- 500 Morange, P. E., Saut, N., Alessi, M. C., Yudkin, J. S., Margaglione, M., Di Minno, G.,
501 ... & Juhan-Vague, I. (2007). Association of plasminogen activator inhibitor
502 (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and
503 metabolic parameters: the HIFMECH study. *Arteriosclerosis, thrombosis, and*
504 *vascular biology*, 27(10), 2250-2257.
- 505 Nikolopoulos, G., Bagos, P., Tsangaris, I., Tsiara, C., Kopterides, P., Vaiopoulos, A.,
506 Kapsimali, V., Bonovas, S. & Tsantes, A. (2014). The association between
507 plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G
508 polymorphism, and myocardial infarction: a Mendelian randomization meta-
509 analysis. *Clinical Chemistry and Laboratory Medicine (CCLM)*, 52(7), 937-950.
510 <https://doi.org/10.1515/cclm-2013-1124>
- 511 Özbek, N., Ataç, F. B., Verdi, H., & Kayiran, S. M. (2003). Purpura fulminans in a child
512 with combined heterozygous prothrombin G20210A and factor V Leiden
513 mutations. *Annals of hematology*, 82, 118-120.
- 514 Raptopoulou, A., Michou, V., Mourtzi, N., Papageorgiou, E. G., Voyiatzaki, C.,
515 Tsilivakos, V., ... & Bei, T. A. (2022). Large-scale screening for factor V Leiden
516 (G1691A), prothrombin (G20210A), and MTHFR (C677T) mutations in Greek
517 population. *Health Science Reports*, 5(4), e457.
- 518 Sabbagh, A. S., Mahfoud, Z., Taher, A., Zaatari, G., Daher, R., & Mahfouz, R. A.
519 (2008). High prevalence of MTHFR gene A1298C polymorphism in Lebanon.
520 *Genetic Testing*, 12(1), 75-80.
- 521 Settin, A. A., Alghasham, A., Ali, A., Dowaidar, M., & Ismail, H. (2012). Frequency of
522 thrombophilic genetic polymorphisms among Saudi subjects compared with other
523 populations. *Hematology*, 17(3), 176-182.
- 524 Tsai, S. J., Hong, C. J., Liou, Y. J., Yu, Y. W. Y., & Chen, T. J. (2008). Plasminogen
525 activator inhibitor-1 gene is associated with major depression and antidepressant
526 treatment response. *Pharmacogenetics and genomics*, 18(10), 869-875.

- 527 Xu X, Wang H, Li H, Cui X, Zhang H. SERPINE1 -844 and -675 polymorphisms and
528 chronic obstructive pulmonary disease in a Chinese Han population. *Journal of*
529 *International Medical Research*. 2016;44(6):1292-1301.
530 doi:10.1177/0300060516664270
- 531 Xu, Y., Duan, L., Wong, D. W. K., Wong, T. Y., & Liu, J. (2016). Semantic
532 reconstruction-based nuclear cataract grading from slit-lamp lens images. In
533 *Medical Image Computing and Computer-Assisted Intervention-MICCAI 2016:*
534 *19th International Conference, Athens, Greece, October 17-21, 2016, Proceedings,*
535 *Part III 19* (pp. 458-466). Springer International Publishing.
- 536 Yang, S., Yu, W., Wei, X., Wang, Z., Zhao, Y., Zhao, X., ... & Zhang, X. (2020). An
537 extended KASP-SNP resource for molecular breeding in Chinese cabbage
538 (*Brassica rapa* L. ssp. *pekinensis*). *Plos one*, 15(10), e0240042.
- 539 Yapijakis, C., Serefoglou, Z., & Voumvourakis, C. (2015). Common Gene
540 Polymorphisms Associated with Thrombophilia. In (Ed.), *Thrombosis,*
541 *Atherosclerosis and Atherothrombosis - New Insights and Experimental Protocols.*
542 IntechOpen. <https://doi.org/10.5772/61859>
- 543 Yapijakis, C., Serefoglou, Z., Nixon, A. M., Vylliotis, A., Ragos, V., & Vairaktaris, E.
544 (2012). Prevalence of thrombosis-related DNA polymorphisms in a healthy Greek
545 population. *in vivo*, 26(6), 1095-1101.
- 546 Yousef, A. M., Shomaf, M., Berger, S., Ababneh, N., Bobali, Y., Ali, D., ... & Ismail, S.
547 (2013). Allele and genotype frequencies of the polymorphic
548 methylenetetrahydrofolate reductase and colorectal cancer among Jordanian
549 population. *Asian Pacific Journal of Cancer Prevention*, 14(8), 4559-4565.
- 550 Zhang, Y., Liang, D., Huang, H., Yang, Z., Wang, Y., Yu, Y., ... & Xiao, W. (2020).
551 Development and application of KASP assays for rapid screening of 8 genetic
552 defects in Holstein cattle. *Journal of Dairy Science*, 103(1), 619-624.